- Wall Street slides amid Fed meeting concerns, potential Ukraine conflict; Dow Jones, S&P 500, Nasdaq Composite witness sharp fal
- Axis Bank Q3FY22 Earnings: PAT up 224% YoY to Rs 3614 cr on strong deposit and loan growth; NII up 17%
- Budget 2022 Expectations: From access to laptops at schools, universities to support to EdTech startups - check budget wishlist
- Swiggy raises Rs 5,225 crore from Invesco; to advance core platform, grow quick commerce grocery service Instamart
Cipla
Global View: ICICI Bank, Bandhan Bank, Cipla and Container Corp could give 15-40% return in long term
Mon, Jan 24, 2022
The Indian markets are likely to witness some volatility on Monday tracking weak global cues, but there will be stock-specific action in which global brokerage came out with their reports on business development, or earnings outlook.
More >
Cipla receives USFDA nod to market Lanreotide injection in American market
Sun, Dec 19, 2021
Drug major Cipla on Sunday said it has received approval from the US health regulator to market the Lanreotide injection, used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors, in the American market
More >
Freaky Friday: Markets witness freefall - These stocks led the plunge but pharma scrips shone
Fri, Nov 26, 2021
As the bears grip the market during Friday’s session, metal, auto, and pharma stocks witnessed a maximum buzz. In this regard, JSW Steel, Tata Motors, Hindalco slipped most, while Cipla and Dr Reddy’s were the top gainers in the otherwise negative market.
More >
Cipla Q2FY22 Results: Consolidated Net up 7% at Rs 711 cr amid strong performance
Tue, Oct 26, 2021
Drug major Cipla on Tuesday said its consolidated profit after tax (PAT) rose by 7 per cent to Rs 711 crore for the second quarter ending September, aided by strong performance in the domestic as well as international markets.
More >
Lupin, Glenmark, JB chemicals, Cipla, Aurobindo potential winners to ride $183 bn cardiac therapy market
Thu, Sep 30, 2021
Cardiovascular disease (CVD) is the leading cause of mortality and accounts for one-third of global deaths. Cardiac has displaced anti-infectives as the leading therapy in the India Pharma Market (IPM).
More >
Nifty Pharma set for 14,600 levels - 3 stocks to buy on Wednesday for gains, says Centrum Broking analyst
Wed, Sep 29, 2021
Sun Pharmaceuticals – The shares of Sun Pharma today ended at Rs 790.50 on Tuesday, up 3.6 per cent from the Monday closing price. He puts target price at Rs 850-Rs 880 with a stop loss at Rs 755. The stock has seen some correction after attaining a 52-week high of Rs 804.35 on 3 August
More >
Stocks to Buy on Monday – Cipla, Vardhman Textiles, Poly Medicure are intraday F&O, cash market, positional picks for these targets
Sun, Sep 19, 2021
Sandeep Jain recommends Cipla as an intraday pick on Monday. This is from the F&O segment. This stock was recommended at Rs 954. He puts the target price at Rs 965 while the stop loss at Rs 947
More >
Cipla shares hit NEW HIGH as DCGI approves to import Moderna’s Covid vaccine – check what analyst suggests for the stock investors
Wed, Jun 30, 2021
As Drugs Controller General of India (DCGI) allowed Cipla to import Moderna’s Covid-19 vaccine, the shares of the pharma major hit a new 52-week high of Rs 997.20 after rallying almost two per cent on the BSE intraday trade on Wednesday. The stock has surged around four per cent since Monday.
More >
Stock Markets CLOSING BELL! BSE Sensex, NSE Nifty 50 close in red; Power Grid, Nestle, Cipla among top gainers; bank, IT, metal stocks fall
Tue, Jun 29, 2021
Stock Markets ended in the red on Tuesday. The BSE Sensex closed at 52,567.30 today, down by over 168 points or 0.3 per cent. Meanwhile, the broader Market NSE Nifty 50 ended at 15,748.45, down by 66 points or 0.4 per cent
More >
Top Stocks to Buy – Amid high market volatility, analyst Sandeep Jain recommends Cipla, Timken India, KEC International for bumper returns
Sun, Jun 20, 2021
The stock markets on Friday traded with high volatility. The markets opened without much noise and then fell steeply. Nifty 50 had a free fall and touching around levels of 15,450 on the intraday basis which was a crucial level. The previous lifetime was 15,431 and the markets took a support at this level. Market Analyst Sandeep Jain said that last trading session of the week was extremely action packed.
More >
Cipla will maintain its EBITDA at 22% in FY22, says Kedar Upadhye
Thu, May 20, 2021
Kedar Upadhye, Global Chief Finance Officer, Cipla, talks about March quarter numbers, market share of Albuetrol in the US market, the deal with Eli Lilly for the drug Baricitinib, production of Remedisvir black fungus drug and guidance for FY22 among others during a candid chat with Swati Khandelwal, Zee Business.
More >
Cipla will maintain its EBITDA at 22% in FY22: Kedar Upadhye
Wed, May 19, 2021
Kedar Upadhye, Global Chief Finance Officer, Cipla, talks about March quarter numbers, market share of Albuetrol in the US market, the deal with Eli Lilly for the drug Baricitinib, production of Remedisvir black fungus drug and guidance for FY22 among others during a candid chat with Zee Business Executive Swati Khandelwal
More >
Cipla share price up nearly 2% despite weak markets: Sharekhan maintains Buy, price target of Rs 1100
Wed, May 19, 2021
Cipla share price: Sharekhan says that Cipla Limited reported strong numbers for Q4FY2021 yoy, though it missed estimates. Results reflect a one time adjustments in gross margins to the tune of 200 bps on account of inventory adjustment for gAlbuterol and charge on material cost inventories. Revenue, at Rs 4606.5 cr, grew by 5% yoy, driven by a 17% rise in US revenues; sales from emerging markets and India grew by 4% yoy each
More >
Cipla Q4 below street estimates: Know what brokerage firms have to say – check target price here
Mon, May 17, 2021
Amid the fourth quarter results being sharply below estimates, the brokerage firms post mixed sentiments towards the pharma major Cipla. However, the company reported a 68 per cent jump in the consolidated net profit in the March-ended quarter of the financial year 2020-2021.
More >
